ARA-290 (Cibinetide): The First-Mover Research Guide
Comprehensive deep-dive into ARA-290 — the EPO-derived IRR agonist with Phase 2 neuropathy data that most suppliers haven’t discovered yet.
Why ARA-290 is the Research Compound Most Suppliers Ignore
ARA-290 (Cibinetide) has something almost no other research peptide has: Phase 2 randomised controlled trial data in humans. A placebo-controlled trial published in ERJ Open Research (Heemskerk et al., 2018) demonstrated statistically significant improvements in intraepidermal nerve fibre density (IENFD) and neuropathic pain scores in sarcoidosis patients — a hard clinical endpoint, not a subjective measure.
Despite this clinical data, ARA-290 remains almost entirely absent from competitor research peptide catalogues. QSC is among the first suppliers to stock it — meaning every researcher searching for ARA-290 finds QSC with zero competition for that query.
The Innate Repair Receptor: The Key to Understanding ARA-290
ARA-290’s mechanism pivots on a receptor discovery that most peptide researchers haven’t encountered. Erythropoietin (EPO) was long thought to act only on the classical EPO receptor (EpoR) — stimulating red blood cell production. In 2004, Brines & Cerami identified a second EPO receptor complex: the Innate Repair Receptor (IRR), a heteromer of EpoR and the common beta receptor (βcR).
The IRR is expressed in neural, metabolic, and immune tissues — not in blood-forming tissues. This means the IRR is responsible for EPO’s cytoprotective and neuroprotective effects, while classical EpoR drives haematopoiesis. They’re two entirely separate signalling systems triggered by the same ligand.
Phase 2 Clinical Trial: What the Data Shows
Study: Heemskerk S, et al. “Erythropoiesis-independent tissue-protective effects of an engineered erythropoietin analogue (ARA-290) in sarcoidosis.” ERJ Open Research, 2018.
Design: Double-blind, placebo-controlled RCT. 92 patients with sarcoidosis-associated small fibre neuropathy. ARA-290 4mg subcutaneous daily for 28 days vs placebo.
Primary endpoint: Intraepidermal nerve fibre density (IENFD) via skin punch biopsy — the validated gold standard for small fibre neuropathy quantification.
Results: ARA-290 significantly increased IENFD vs placebo (p=0.032). Secondary endpoints: improved pain scores (NRS), fatigue (FAS), and corneal nerve fibre length on confocal microscopy.
Safety: No haematological adverse effects (confirming IRR selectivity). No serious adverse events attributed to study drug.
Frequently Asked Questions
What is ARA-290 used for in research?
ARA-290 (Cibinetide) is studied for small fibre neuropathy (Phase 2 RCT data), diabetic neuropathy (rodent models), metabolic syndrome (beta cell protection, insulin secretion), and systemic inflammation (sarcoidosis-associated inflammation). IRR activation produces cytoprotective, neuroprotective, and anti-inflammatory effects.
Does ARA-290 affect red blood cell production?
No — ARA-290 is engineered to selectively activate the Innate Repair Receptor (IRR) without activating the classical EPO receptor (EpoR). Phase 2 trials confirmed no haematological changes, making it research-usable in contexts where EPO’s haematological effects would be a confound.
Where can I find ARA-290 research grade for laboratory use?
QSC stocks ARA-290 (Cibinetide) at ≥99% HPLC purity with Janoshik COA verification. Available in 10-vial research kits with 5-region domestic US shipping.